Oxford Immunotec Global (NASDAQ: OXFD) is one of 25 public companies in the “Diagnostic substances” industry, but how does it compare to its competitors? We will compare Oxford Immunotec Global to similar companies based on the strength of its analyst recommendations, profitability, valuation, risk, earnings, dividends and institutional ownership.
Valuation and Earnings
This table compares Oxford Immunotec Global and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Oxford Immunotec Global||$103.08 million||-$32.88 million||-9.72|
|Oxford Immunotec Global Competitors||$308.35 million||$13.85 million||-44.26|
This is a breakdown of current recommendations and price targets for Oxford Immunotec Global and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Oxford Immunotec Global||0||0||4||0||3.00|
|Oxford Immunotec Global Competitors||102||369||569||19||2.48|
Oxford Immunotec Global currently has a consensus target price of $18.75, indicating a potential upside of 41.83%. As a group, “Diagnostic substances” companies have a potential upside of 8.27%. Given Oxford Immunotec Global’s stronger consensus rating and higher possible upside, analysts clearly believe Oxford Immunotec Global is more favorable than its competitors.
Risk and Volatility
Oxford Immunotec Global has a beta of -0.32, meaning that its share price is 132% less volatile than the S&P 500. Comparatively, Oxford Immunotec Global’s competitors have a beta of 1.44, meaning that their average share price is 44% more volatile than the S&P 500.
This table compares Oxford Immunotec Global and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Oxford Immunotec Global||-31.90%||-42.38%||-23.65%|
|Oxford Immunotec Global Competitors||-885.83%||-65.54%||-25.27%|
Institutional and Insider Ownership
93.3% of Oxford Immunotec Global shares are held by institutional investors. Comparatively, 53.1% of shares of all “Diagnostic substances” companies are held by institutional investors. 8.1% of Oxford Immunotec Global shares are held by company insiders. Comparatively, 13.5% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Oxford Immunotec Global beats its competitors on 8 of the 13 factors compared.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.